Check-Cap(US:CHEK)2019-09-18 19:04Overview - Check-Cap aims to prevent colorectal cancer (CRC) through precancerous polyp detection using a prep-free capsule-based alternative [3, 4] - The company's C-Scan system has received CE Mark approval and is approved for sale in Israel, with a U S clinical study underway [4] - CRC is the third most diagnosed cancer worldwide, with approximately 18 million new cases and 881000 deaths annually [7] Market Opportunity - The global market opportunity for CRC screening is estimated to be multi-billion dollar, with potential markets of approximately $9 billion in the United States, $20 billion in Europe, and $30 billion in China [7, 10, 11, 12] - Screening rates remain low in the US, Germany and China [6] - The American Cancer Society (ACS) recommends screening every 10 years for average-risk patients aged 50-75, with revised guidelines recommending screening to begin at age 45 [13] C-Scan Technology and Clinical Data - C-Scan is a prep-free polyp detection system consisting of a capsule, tracking system, and post-processing suite [14] - Post-CE approval study results showed C-Scan sensitivity of 76% for polyps ≥10mm and 100% for polyps ≥40mm [19] - C-Scan demonstrated 82% specificity in the post-CE approval study [20] Commercialization and Intellectual Property - GE Healthcare has completed the manufacturing line for C-Scan [22, 25] - Pilot sales are planned to initiate in Israel in 2020 and in the EU in 2021 [23, 24] - Check-Cap has a strong global intellectual property portfolio with 41 patents granted and 22 pending [27] Financial Information - As of June 30, 2019, Check-Cap had $147 million in cash and equivalents [34]